Angioimmunoblastic T-cell lymphoma

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma

Retrieved on: 
Tuesday, August 8, 2023
Lymphoma, PTCL, Peripheral T-cell lymphoma, Hematopoietic stem cell transplantation, ASH, Angioimmunoblastic T-cell lymphoma, Lymphoproliferative disorders, Creatinine, DLBCL, Thomas Jefferson University, Aes, Valganciclovir, Constipation, Oncology, Histone deacetylase inhibitor, B-cell lymphoma, Bone marrow, Patient, Division, American Society of Hematology, Data, SAN, PTLD, PTCL-NOS, Cytopenia, Nausea, Paper, CRS, Therapy, Society, ORR, Disease, Vaccine, Pharmaceutical industry, Hematology

SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the publication of clinical data from an open-label, multicenter, Phase 1b/2 study of Nana-val in 55 patients with R/R EBV+ lymphoma in Blood Advances. Results showed complete responses (CRs) achieved and ongoing durable responses observed out to approximately 36 months across multiple EBV+ lymphoma subtypes, including some of the most aggressive cancers: peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL), and post-transplant lymphoproliferative disease (PTLD). This paper titled, “Targeted therapy with nanatinostat and valganciclovir in recurrent Epstein-Barr virus-positive lymphoid malignancies: a Phase 1b/2 study,” can be found here.

Key Points: 
  • This paper titled, “Targeted therapy with nanatinostat and valganciclovir in recurrent Epstein-Barr virus-positive lymphoid malignancies: a Phase 1b/2 study,” can be found here .
  • The published paper includes an additional 10-month follow-up period, which demonstrated durable response durations across multiple EBV+ lymphoma subtypes.
  • Overall, trial participants received a median of two prior therapies before entering the trial, with 75% (41/55) being refractory to their last therapy.
  • Initial data from the Nana-val Phase 1b/2 clinical trial were previously presented at the 2021 American Society of Hematology (ASH) Annual Meeting .

Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association

Retrieved on: 
Thursday, May 11, 2023
PTCL, Abstract, Index, Angioimmunoblastic T-cell lymphoma, AE, European Hematology Association, REDIRECT, ADCC, Progression-free survival, Bone marrow, Grade 3, Cancer, FDG-PET, NK, Cell, IRR, Redirect, AML, CD123, EHA, MTD, ORR, Safety, Pharmaceutical industry, Vaccine, Patient

HEIDELBERG, Germany, May 11, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that two abstracts have been accepted to EHA2023, the annual meeting of the European Hematology Association (EHA) taking place in Frankfurt, Germany on June 8-11, 2023.

Key Points: 
  • HEIDELBERG, Germany, May 11, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that two abstracts have been accepted to EHA2023, the annual meeting of the European Hematology Association (EHA) taking place in Frankfurt, Germany on June 8-11, 2023.
  • In the REDIRECT study, the AFM13 innate cell engager (ICE®) exhibited clinical efficacy in a heavily pre-treated CD30-positive r/r PTCL population.
  • Overall, the objective response rate (ORR) based on FDG-PET assessed by an independent review committee was 32.4%, thus comparable to therapies approved for this indication.
  • The median duration of response, progression-free survival, and overall survival were 2.3, 3.5, and 13.8 months, respectively.

Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Patient, ORR, Angioimmunoblastic T-cell lymphoma, Company, Progression-free survival, Fatigue, B-cell lymphoma, Therapy, Risk, III/IV, PM, Society, PRS, Peripheral T-cell lymphoma, NDAS, Safety, IND, Time in China, GemOx, ASH, Relapse, SEHK, PFS, Extranodal NK/T-cell lymphoma, nasal type, Nature, CEO, NDA, LAUNCH, CR, Nausea, Greater, Annual report, Hematology, Vomiting, Genta (company), Hong Kong Stock Exchange, ET, ALCL, Natural killer cell, SDS, Time, Phases of clinical research, PTCL-NOS, Fine chemical, Pharmaceutical industry, Dexamethasone

SHANGHAI and HONG KONG, Nov. 6, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, today announced that it will present updated results from the Phase Ib TOUCH study of selinexor for treatment of R/R T and NK-cell lymphoma in a poster at the upcoming 2022 American Society of Hematology (ASH) Annual Meeting. In addition, preliminary results from the investigator-initiated LAUNCH trial will be published in an on-line abstract. The 2022 ASH Annual Meeting will be held virtually and in person in New Orleans, Louisiana, the United States, from December 10-13, 2022.

Key Points: 
  • In addition, preliminary results from the investigator-initiated LAUNCH trial will be published in an on-line abstract.
  • The 2022 ASH Annual Meeting will be held virtually and in person in New Orleans, Louisiana, the United States, from December 10-13, 2022.
  • "The data to be presented at ASH 2022 highlights the broad clinical potential and manageable side effect profile of selinexor in patients with well-defined T-cell lymphomas and R/R MM," said Dr. Jay Mei, Antengene's Founder, Chairman and CEO.
  • "It is our great pleasureto share these updates with the hematology/oncology community at ASH 2022."

Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

Retrieved on: 
Monday, December 13, 2021
U.S. Securities and Exchange Commission, Food, AML, Company, KURA, Adult, Nasdaq, Progression-free survival, Fatigue, Biomarker, DOR, ORR, Cancer, HNSCC, SEC, Survival, Hematology, Breakthrough therapy, T-cell lymphoma, Neutropenia, Thrombocytopenia, Anemia, Lymphatic system, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, Research, NPM1, Safety, Patient, Nausea, Therapy, Security (finance), Angioimmunoblastic T-cell lymphoma, Patent, KMT2A, Fast Track, GLOBE, ASH, HRAS, Tipifarnib, Mayo Clinic, News, Society, Diarrhea, Pharmaceutical industry, Janssen

SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced final results from a Phase 2 study of tipifarnib as a monotherapy in patients with relapsed or refractory T-cell lymphoma, including an overall response rate (ORR) of 56% and a median overall survival of 32.8 months in heavily pretreated patients with angioimmunoblastic T-cell lymphoma (AITL).

Key Points: 
  • The final results are being presented during an oral session today at the American Society of Hematology (ASH) Annual meeting in Atlanta.
  • A total of 65 patients with relapsed or refractory T-cell lymphoma were enrolled in the study, with a median of three prior regimens (range 1-8).
  • Tipifarnib was generally well-tolerated in this Phase 2 study, with adverse events consistent with its known safety profile.
  • This multi-center, single-arm, open-label Phase 2 study was designed to evaluate tipifarnib as a monotherapy in adult patients with relapsed or refractory T-cell lymphoma.

Kura Oncology Reports Third Quarter 2021 Financial Results

Retrieved on: 
Thursday, November 4, 2021
Society, Population, Safety, AML, Cancer, HNSCC, News, Novartis, Drug resistance, MD Anderson Cancer Center, Security (finance), KURA, Hand, FTI, Acute myeloid leukemia, ASH, HRAS, Investment, NPM1, PTCL, T-cell lymphoma, Research, Angioimmunoblastic T-cell lymphoma, Company, U.S. Securities and Exchange Commission, GLOBE, Therapy, Mayo Clinic, Pharmacokinetics, Hematology, Webcast, Tipifarnib, Survival, Nasdaq, Breakthrough therapy, Patient, Head, Risk, IND, Pharmaceutical industry, Lithium, Cryptocurrency

ET

Key Points: 
  • ET
    SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2021 financial results and provided a corporate update.
  • Research and development expenses for the third quarter of 2021 were $22.4 million, compared to $16.6 million for the third quarter of 2020.
  • General and administrative expenses for the third quarter of 2021 were $11.3 million, compared to $7.6 million for the third quarter of 2020.
  • ET / 1:30 p.m. PT today, November 4, 2021, to discuss the financial results for the third quarter 2021 and provide a corporate update.

Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

Retrieved on: 
Sunday, December 8, 2019
Life sciences, Medical specialties, Articles, Angioimmunoblastic T-cell lymphoma, Non-Hodgkin lymphoma, Tipifarnib, Lymphoma, Stromal cell-derived factor 1, T-cell lymphoma, Biopharmaceutical, Oncology

We are encouraged by our growing body of data for tipifarnib in AITL, said Antonio Gualberto, M.D., Ph.D., Head of Development and Chief Medical Officer of Kura Oncology.

Key Points: 
  • We are encouraged by our growing body of data for tipifarnib in AITL, said Antonio Gualberto, M.D., Ph.D., Head of Development and Chief Medical Officer of Kura Oncology.
  • Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive form of T-cell lymphoma frequently characterized by high levels of CXCL12 expression.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
  • In addition, tipifarnib is being evaluated in multiple other Phase 2 clinical trials in solid tumor and hematologic indications.

Global Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Clinical Trials Review, H2, 2018 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 26, 2019
Health, Clinical trials, Pharmaceutical, Health, Medical specialties, Clinical research, Medicine, Lymphoma, Angioimmunoblastic T-cell lymphoma, Non-Hodgkin lymphoma, T-cell lymphoma, Clinical trials registry, Clinical trial

The "Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Global Clinical Trials Review, H2, 2018" provides an overview of Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy.
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.